Company
Zynex Medical
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
4
510(k), De Novo and PMA
Device trials
1
As lead sponsor, any status
Adverse event reports
4
Received Nov 1, 2025 to Nov 21, 2026
Recall records
1
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$0
1 Form D offering, 2016 to 2016
Equity
$0
Stock sold for cash
Debt and convertible notes
$0
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: convertible note, $0 raised of $1.5M sought, filed Nov 25, 2016.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Filed Nov 25, 2016 | Convertible note | $0 | $1.5M | 0 | Rule 506(b), Securities Act 4(a)(5)Agent: Newbridge Securities CorporationCommissions $195K | Form D ↗Nov 25, 2016 |
Company details
From the company's latest Form D.
- Legal name
- ZYNEX INC
- Headquarters
- Lone Tree, Colorado
- Incorporated
- Nevada over five years before filing
- Entity type
- Corporation
- Revenue range
- $5,000,001 - $25,000,000
- Industry filed under
- Other Health Care
- SEC filer
- CIK 846475 ↗
Executives, directors and promoters
As listed on the latest Form D.
1 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors from funding announcements and the firms' own portfolio pages.
No 5%+ shareholder filings, SBIR grants or venture investors found under the name Zynex Medical.
Latest FDA decisions
- TENSWave510(k)
K241228 · Decided Aug 27, 2024 · 117 days after receipt
Device type: Stimulator, Nerve, Transcutaneous, For Pain Relief (GZJ) · Neurology & Neurosurgery
3 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Randomized Blinded Evaluation of the Effects of TENS and IFC Compared to a Sham Device and SOC in Patients With Non-Specific CLBPPivotal-lookingCompleted
NCT05972889 · 334 participants · Start Nov 2, 2023 · Primary completion Oct 21, 2025
Device: NexWave; Sham · For: Non-Specific Chronic Lower Back Pain
Sites: Greenwood Village, Colorado; Saint Augustine, Florida; Atlanta, Georgia · 8 sites in all
Reports received
4
Received Nov 1, 2025 to Nov 21, 2026
Malfunction reports
0
0.0% of reports
Injury reports
4
100% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 4 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1874-2014 · Started Jan 25, 2009 · Posted by FDA Jun 26, 2014
Reason given: Zynex notified customers that a malfunction in the IF 8000 can result in the device ceasing to operate, and in some instances,overheating and becoming hot to the touch.
Cause as FDA categorized it: Component design/selection · Device type: Stimulator, Muscle, Powered (IPF)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.